Roger Li, MD, on Bladder Cancer: A Possible New Treatment in CG0070 Plus Pembrolizumab

Roger Li, MD, of the Moffitt Cancer Center, discusses phase II results from the CORE1 study, which examined the combination of CG0070 plus pembrolizumab for patients with non–muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG). Treatment options for this population are needed, as BCG is the only agent approved in the past 20 years to be combined with pembrolizumab.